Orchard Therapeutics plc Profit Margin

Orchard Therapeutics plc (ORTX) currently reports a profit margin of 319.87% as of September 2023. That compares with -1109.0% in the prior-year period — up 128.8% year over year. That is above the Healthcare sector average of 13.89%. Use the charts on this page to explore Orchard Therapeutics plc's profit margin history and peer comparisons.

Orchard Therapeutics plc's profit margin increased from -1109.0% to 319.87% — a 128.8% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Orchard Therapeutics plc's profit margin of 319.87% is higher than the Healthcare sector average of 13.89%. That is roughly 2202.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Orchard Therapeutics plc's current 319.87% should be judged against Healthcare norms (sector average: 13.89%) and against ORTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 319.87%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for Orchard Therapeutics plc, and consider following ORTX for alerts when major investors trade the stock.